US Patent

US11219621 — Methods for treating immunodeficiency disease

Method of Use · Assigned to X4 Pharmaceuticals Inc · Expires 2036-12-22 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating WHIM syndrome or related disorders by administering X4P-001 to reduce CXCR4 activity.

USPTO Abstract

The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity.

Drugs covered by this patent

Xolremdi (MAVORIXAFOR) · X4 Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3932`	—	Xolremdi

Patent Metadata

Patent number: US11219621
Jurisdiction: US
Classification: Method of Use
Expires: 2036-12-22
Drug substance claim: No
Drug product claim: No
Assignee: X4 Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.